钴铬合金或不锈钢球囊扩张裸金属支架治疗髂动脉闭塞性疾病
该回顾性研究比较了钴铬合金Dynetic-35支架与不锈钢Dynamic支架治疗症状性髂动脉闭塞性疾病的表现,纳入2014至2021年间连续患者。结果显示不锈钢组技术成功率显著更高(100% vs 97.3%,p=0.01),1年通畅率、靶病变血运重建率及死亡率两组无显著差异。作者建议在通过钴铬支架时加强注意以避免支架变形。
要点
- 不锈钢支架组技术成功率显著高于钴铬支架组(100% vs 97.3%,p=0.01)。
- 1年主要通畅率钴铬组91.3% vs 不锈钢组93.5%,无显著差异。
- 通过钴铬支架时需加强注意以避免纵向变形或支架移位。
核心结论
- 随访1年,钴铬合金与不锈钢球囊扩张支架治疗髂动脉闭塞性疾病均安全有效。
- 通过钴铬支架时使用血管内器械应加强注意以避免操作并发症。
研究设计与样本
- 回顾性评估2014至2021年间连续接受症状性髂动脉闭塞性疾病治疗的患者。
- 钴铬组159例患者(34.6%女性,平均年龄66.9±9.5岁)使用222枚支架治疗216处病变。
- 不锈钢组182例患者(34.6%女性,平均年龄66.3±9.9岁)使用252枚支架治疗234处髂动脉病变。
主要发现
- 两组平均病变长度(30.2±12.8 mm vs 28.7±22.5 mm,p=0.36)和平均钙化分级(2.0 vs 1.9,p=0.07)无显著差异。
- 钴铬组更多患者服用他汀类药物(p<0.001),不锈钢组更多为活跃吸烟者且Rutherford分级更高(p<0.001)。
- 不锈钢组技术成功率显著更高(100% vs 97.3%,p=0.01),原因为通过Dynetic-35后发生纵向变形或支架移位。
- 1年器械或操作相关死亡(0.6% vs 1.1%,p=0.99)、主要截肢(1.9% vs 1.6%,p=0.99)、主要通畅率(91.3% vs 93.5%)及临床驱动的靶病变血运重建(6.5% vs 2.8%,p=0.07)两组无显著差异。
临床怎么用
- 作者建议通过钴铬支架时使用导丝、导管或鞘管应加强注意以避免支架变形。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To compare the performance of a new-generation cobalt-chromium balloon-expandable bare metal stent with a stainless steel platform for the treatment of iliac occlusive disease. METHODS: Consecutive patients treated for symptomatic iliac occlusive disease between 2014 and 2021 with the cobalt-chromium Dynetic-35 or the stainless steel Dynamic platform were retrospectively evaluated. Outcome measures included technical success, device- or procedure-related death, clinically-driven target lesion revascularization (CD-TLR), primary patency, and major index limb amputation up to 12 months. RESULTS: In total, 222 Cobalt chromium (CC) stents were used in 159 patients (34.6% female; mean age 66.9 ± 9.5 years) for the treatment of 216 lesions, while 234 iliac lesions of 182 patients (34.6% female; mean age 66.3 ± 9.9 years) were treated with 252 stainless steel (SS) stents. The mean lesion length (30.2 ± 12.8 mm vs 28.7 ± 22.5 mm, p=0.36) and the mean calcification grade (2.0 vs 1.9, p=0.07) did not differ significantly between the 2 groups. Patients treated by the CC platform were more frequently on statins (p<0.001), whereas more active smokers and subjects with higher Rutherford class underwent a SS deployment (p<0.001). Technical success was significantly higher in the SS group (100% vs 97.3%; p=0.01). This was due to longitudinal deformation or stent dislocation after passing the Dynetic-35 with endovascular material. After 1 year, no difference was found following CC and SS stent deployment in terms of device- or procedure-related deaths (0.6% vs 1.1%, p=0.99), target limb amputations (1.9% vs 1.6%, p=0.99), primary patency (91.3% vs 93.5%), and CD-TLR (6.5% vs 2.8% p=0.07). CONCLUSIONS: Through 1 year, cobalt-chromium and stainless steel balloon-expandable stents are safe and effective in the treatment of iliac occlusive disease. Enhanced attention should be given passing the cobalt-chromium stent with endovascular devices to avoid procedural complications.Clinical ImpactStents with a thin-strut structure improve the flexibility and deliverability. The lower profile also increases the applicability lowering the risk of vascular access complications. In this study newer-generation cobalt chromium balloon-expandable stent did not confer advantages over stainless steel bare metal stent. On contrary, the technical success was inferior to stainless steel stents as longitudinal deformation or dislocation of the Dynetic-35 occurred. Therefore, enhanced attention should be given passing a Cobalt chromium stent with wires, catheters or sheaths to avoid stent deformation.
引用
- Torsello GF, Stavroulakis K, Chlouverakis G, et al. Cobalt Chromium or Stainless Steel Balloon-Expandable Bare Metal Stents for Iliac Occlusive Disease? J Endovasc Ther. 2024. PMID: 39711490. doi:10.1177/15266028241306068
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。